Chinese Journal of Integrative Medicine

, Volume 24, Issue 3, pp 213–217 | Cite as

Effects of Compound Zhebei Granule (复方浙贝颗粒) Combined with Doxorubicin on Expression of Specific Surface Antigens in Mice with Transplanted KG-1a Cells

  • Yu Zhang
  • li Hou
  • Xin-yi Chen
Original Article



To investigate the effects of Compound Zhebei Granule (复方浙贝颗粒, CZG) combined with doxorubicin hydrochloride (adriamycin, ADM) on specific surface antigens in mice with KG-1a transplanted cells.


A subcutaneous tumor xenograft model was established by injection of the acute myeloid leukemia cell line KG-1a into the axillary flfl anks of BALB/c-nude mice. Twenty-four tumor bearing mice were divided into 4 groups according to a random number table, including normal saline control group, ADM group, high-dose CZG group, and mid-dose CZG group, with 6 mice in each group. Drug administration occurred on the 14th day after cell inoculation, and normal saline control group mice were gavaged with normal saline at 0.2 mL/10 g every other day. ADM group mice were intraperitoneally injected with ADM 1 mg/kg [conversion of adults, 40 mg/(m2•d)] every other day. High- and mid-dose CZG groups mice were gavaged with CZG at the dose of 8 and 4 g/kg respectively every other day and intraperitoneally injected with ADM (1 mg/kg) every other day. The administration period lasted for 10 days. The tumor xenografts were made into mononuclear cell suspensions after dissection, and the expressions of specific surface antigens, including CD34+CD38-, CD34+CD38-CD123+, CD34+CD38-CD96+ and CD34+CD38-CD33+, in KG-1a cell line tumor xenografts were detected by flfl ow cytometry.


Compared with the control and ADM groups, expression of CD34+CD38- in the two CZG groups was significantly lower (P<0.05). Compared with the control group, expression of CD34+CD38-CD123+ in the two CZG groups decreased (P<0.05). The high-dose CZG group showed more obvious outcomes compared with the ADM group (P<0.05). Compared with the control and ADM groups, the expression of CD34+CD38-CD96+ and CD34+CD38-CD33+ in the two CZG groups decreased (P<0.05).


CZG combined with doxorubicin could reduce the expression of CD34+CD38-, CD34+CD38-CD123+, CD34+CD38-CD96+ and CD34+CD38-CD33+ in KG-1a cell line tumor xenografts, which shows that CZG could target leukemia stem cells and play a role in chemosensitization.


acute myeloid leukemia Chinese medicine doxorubicin adriamycin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wang Y, Han HX, Zhang JC, Zhu P. Resistance mechanisms and targeted therapy in leukemia stem cells. J Mod Oncol (Chin) 2011;19:1457–1460.Google Scholar
  2. 2.
    Li DY, TIan SD, Ye PZ, Zhang Y, Chen XY. Study of Compound Zhe Bei Particles improve clinical curative effect of the acute refractory leukemia adjuvant chemotherapy. Beijing J Tradit Chin Med (Chin) 2007;26:72–74.Google Scholar
  3. 3.
    Chen XY, Li DY, Tian SD. Diagnosis and treatment of refractory acute leukemia. J Chin Integr Med (Chin) 2009;29:177–182.Google Scholar
  4. 4.
    Song B, Zhang RY. Expression and its clinical sense of CDl23 on bone marrow stem cells and progenitor cells of patients with acute leukemia. Jiangxi Med J (Chin) 2010;45:305–306.Google Scholar
  5. 5.
    Han YL, Liu X, Li QW. Advances in signal transduction and functional of CD33 molecular. J Shangqiu Norm Univ (Chin) 2010;26(3):1–5.Google Scholar
  6. 6.
    Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with thepoliovirus receptor (CD155). J Immunol 2004;172:3994–3998.CrossRefPubMedGoogle Scholar
  7. 7.
    Gramatzki M, Ludwig WD, Burger R, Moos P, Rohwer P, Grünert C, et al. Antibodies TC-12 ("unique") and TH-111 (CD96) characterize T cell acute lymphoblastic leukemia and a subgroup of acute myeloid leukemia. Exp Hematol 1998;126:1209–1214.Google Scholar
  8. 8.
    Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H. CD96 is a leukemia stem cell specific marker in human acute myeloid leukemia. Proc Natl Acad Sci USA 2007;104:11008–11013.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wu Y, Xiao M, Zhu L, Zhou XX, Long Q, Xin X, et al. CD96 expression on bone marrow mononuclear cells in 91 patients with acute leukemia. J Exp Hematol (Chin) 2011;19:585–588.Google Scholar
  10. 10.
    She MR, Niu XQ, Chen XL, Li JG, Zhou MH, He YJ, et al. Resistance of leukemic stem-like cells in AML cell line KG-1a to natural killer. Cancer Let 2012;318:173–179.CrossRefGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2017

Authors and Affiliations

  1. 1.Department of Integrated Chinese and Western Medicine, Tianjin Medical University Cancer Institute and HospitalNational Clinical Research Center for Cancer TianjingTianjingChina
  2. 2.Key Laboratory of Cancer Prevention and TherapyTianjinChina
  3. 3.Tianjin Clinical Research Center for CancerTianjinChina
  4. 4.Department of HematologyDongzhimen Hospital Affiliated to Beijing University of Chinese MedicineBeijingChina

Personalised recommendations